ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 234 entries already.
The geographical proximity of Spains Northwestern region Galicia to Northern Portugal is a key factor for the birth of the new bioregion CT-Bio. This achievement looks forward to improving business competitiveness and the consolidation of the biotech and life sciences sector internationally.
Basel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million.
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.
Expedeon has sold its immunology and proteomics business activities to global life sciences company Abcam. Abcam is paying €120m in cash for the business.
Dutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the development, manufacturing and supply of the collaboration biosimilar, which is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents while using dedicated efficient lysis reagents for e.g. different plant tissues. In contrast to common bind-wash-elute procedures, the process does not require washing steps. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
The FDA has given the go-ahead to PharmaMars proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.
Together with the EIB, five of the EUs largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.